15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Edgewise Therapeutics Inc, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $32.00 to $59.00, a moderate spread. The average target of $48.75 sits 17% above the current $41.59. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.13 next quarter toward $-1.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Edgewise Therapeutics Inc.
As of Jul, 7 of 8 firms rate EWTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EWTX EPS & revenue forecast
EPS · NEXT QUARTER
$1.13
Range $-0.62 – $9.36 · 6 analysts · -390% YoY
Next period, 6 analysts expect Edgewise Therapeutics Inc to earn $1.13 a share (range $-0.62 – $9.36), versus $-0.39 a year earlier. Full-year consensus is $-0.23, growing to $-1.47 the year after.
REVENUE · NEXT QUARTER
$193.8M
Range $0 – $1.6B · 6 analysts
Revenue is expected to reach $193.8M (range $0 – $1.6B). Full-year consensus is $209.4M, rising to $52.5M next year.
Top analysts covering Edgewise Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EWTX.
#1
Leonid Timashev
RBC Capital · Rank #69
Buy
$59.00+41.9% to target
Overall win rate
42%
+ Follow
#2
Laura Chico
Wedbush · Rank #122
Buy
$52.00+25.0% to target
Overall win rate
40%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$51.00+22.6% to target
Overall win rate
34%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$45.00+8.2% to target
Overall win rate
32%
+ Follow
#5
TR
Tessa Romero
JP Morgan
Buy
$53.00+27.4% to target
Coverage
—
+ Follow
EWTX stock forecast FAQ
What is EWTX's average 12-month price target?+
The 8 analysts with a live target average $48.75 for Edgewise Therapeutics Inc over the next 12 months, ranging from a $59.00 high to a $32.00 low.
Is EWTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for EWTX?+
The Street-high target is $59.00 (RBC Capital), and the Street-low is $32.00 (Goldman Sachs). The average of all 8 active targets is $48.75.
How many Wall Street analysts cover EWTX?+
8 analysts have an active rating on Edgewise Therapeutics Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering EWTX?+
Among analysts who currently cover EWTX, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $59.00 target.
What is Edgewise Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $1.13 per share (range $-0.62 – $9.36) across 6 analysts. Full-year EPS is projected at $-0.23, rising to $-1.47 the following year.
How much revenue is Edgewise Therapeutics Inc expected to report next quarter?+
Consensus revenue is $193.8M (range $0 – $1.6B). Full-year revenue is projected at $209.4M, growing to $52.5M next year.
Have analysts been upgrading or downgrading EWTX lately?+
As of Jul, 7 of 8 firms rate EWTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EWTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Oppenheimer
